Brentview Investment Management Boosts Johnson & Johnson Holdings

Institutional investor increases stake in pharmaceutical giant by 25.5% in Q3

Mar. 11, 2026 at 8:52am

Got story updates? Submit your updates here. ›

Brentview Investment Management LLC, an institutional investor, increased its holdings in Johnson & Johnson (NYSE: JNJ) by 25.5% during the third quarter, according to a recent SEC filing. The firm now owns 26,266 shares of the company's stock, valued at $4.87 million.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Institutional investors closely monitor changes in ownership of major blue-chip stocks like JNJ, as it can signal broader market trends and investor sentiment.

The details

Brentview Investment Management, an institutional investor based in New Jersey, disclosed in a regulatory filing that it increased its stake in Johnson & Johnson by 5,337 shares, or 25.5%, during the third quarter of 2026. The firm now holds a total of 26,266 shares of JNJ, making it the 22nd largest holding in its investment portfolio.

  • Brentview Investment Management increased its Johnson & Johnson holdings during the 3rd quarter of 2026.

The players

Brentview Investment Management LLC

An institutional investment firm based in New Jersey that manages a portfolio of stocks, including a significant position in pharmaceutical giant Johnson & Johnson.

Johnson & Johnson

A multinational healthcare company headquartered in New Brunswick, New Jersey that develops, manufactures, and markets a broad range of pharmaceutical, medical device, and consumer health products.

Got photos? Submit your photos here. ›

The takeaway

Brentview's increased stake in Johnson & Johnson reflects the continued appeal of the company's diversified healthcare business model and its status as a blue-chip investment. The move also highlights the ongoing interest from institutional investors in large, established pharmaceutical firms with strong market positions.